Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Cancer Statistics, 2009

2009 • 9,675 citations

World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997

1999 • 3,357 citations

Follicular lymphoma international prognostic index.

2004 • 1,553 citations

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

2005 • 1,310 citations

Follicular lymphoma international prognostic index

2006 • 1,262 citations

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

2010 • 1,010 citations

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

2004 • 971 citations

Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy

1999 • 878 citations

The World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues

1999 • 820 citations

Rituximab: Mechanism of Action

2010 • 707 citations

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2017 • 678 citations

Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma

2008 • 579 citations

Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study

2007 • 498 citations

Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma

2005 • 441 citations

Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysis

2007 • 363 citations

Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma

2008 • 354 citations

Non-Hodgkin’s Lymphomas

2010 • 337 citations

Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study

2008 • 327 citations

Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study

2008 • 297 citations

Follicular Lymphoma in the United States: First Report of the National LymphoCare Study

2009 • 280 citations

Bendamustine: Rebirth of an Old Drug

2009 • 264 citations

Bendamustine is effective therapy in patients with rituximab‐refractory, indolent B‐cell non‐Hodgkin lymphoma

2009 • 245 citations

Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches

2004 • 153 citations

Non-Hodgkin's Lymphomas

2011 • 149 citations

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2011 • 79 citations

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

2009 • 36 citations

Current treatment standards and future strategies in mantle cell lymphoma

2008 • 23 citations